

## PRESS RELEASE

Stockholm, Sweden, 8 August 2016



### Sobi's CEO divests a portion of shares

[Swedish Orphan Biovitrum AB's \(publ\)](#) (Sobi™) CEO Geoffrey McDonough has divested 300,000 of the shares he holds in the company. The sale was made for personal financial reasons. After the transaction, the CEO will hold a total of 347,948 shares in the company.

---

#### About Sobi™

Sobi™ is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm.

#### For more information please contact

Media relations

Charlotte af Klercker, Sr Communications Manager

T: +46-707-297 327

[charlotte.afklercker@sobi.com](mailto:charlotte.afklercker@sobi.com)

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

[jorgen.winroth@sobi.com](mailto:jorgen.winroth@sobi.com)

Swedish Orphan Biovitrum AB

Postal address SE-112 76 Stockholm, Sweden

Phone: +46 8 697 20 00 [www.sobi.com](http://www.sobi.com)